t.tulloch, post #70: Coming back to post #68, because the follow-up matters more than the original answer. Hepatic impairment: less is known about dosing in significant liver disease than in kidney disease. Extreme caution applies because the liver metabolises a large fraction of many medications.
Go to post
I read post #119 twice before replying, because I had assumed the opposite.
Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is extrapolating beyond the data.